Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 29, Issue 5, 2008, Pages 333-338

  Capaccio, Pasquale ^a   Torretta, Sara ^a   Osio, Maurizio ^b   Minorati, Davide ^b   Ottaviani, Francesco ^b   Sambataro, Giuseppe ^a   Nascimbene, Cristina ^b   Pignataro, Lorenzo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; FEMALE; FREY SYNDROME; HUMAN; HYPERSALIVATION; MALE; PAROTITIS; PRIORITY JOURNAL; SALIVARY FISTULA; SALIVARY GLAND DISEASE; SALIVARY SECRETORY DISORDER; SIALOGRAPHY; STALOCELE; SWEAT GLAND DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SALIVARY GLAND DISEASES; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; SIALOGRAPHY; SIALORRHEA; TREATMENT OUTCOME;

EID: 49649127326     PISSN: 01960709     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjoto.2007.10.003     Document Type: Article

References (30)

1. Bushara K.O. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment-botulinum toxin A injections of the parotid glands. Med Hypotheses 48 (1997) 337-339
2. DasGupta B.R., and Sugiyama H.A. A common subunit structure in Clostridium botulinum type A, B, and E toxins. Biochem Biophys Res Commun 48 (1972) 108-112
3. Blitzer A., and Sulica L. Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 111 (2001) 218-226
4. Brin M.F. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In: Blitzer A., Binder W.J., Boyd J.B., et al. (Eds). Management of facial lines and wrinkles (2002), Lippincott Williams & Wilkins, Philadelphia 279-302
5. Marchese-Ragona R., De Filippis C., Staffieri A., et al. Parotid gland fistula: treatment with botulinum toxin. Plast Reconstr Surg 107 (2001) 886-887
6. Guntinas-Lichius O. Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A. Laryngoscope 113 (2003) 743-745
7. Turk-Gonzales M., and Odderson I.R. Quantitative reduction of salivary production with botulinum toxin type B injection into the salivary glands. Neurorehabil Neural Repair 19 (2005) 58-61
8. Sollner T., Bennett M.K., Whiteheart S., et al. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion. Cell 75 (1993) 409-418
9. Ellies M., Laskawi R., Rohrbach-Volland S., et al. Botulinum toxin to reduce salivary flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 112 (2002) 82-86
10. Ellies M., Gottstein U., Rohrbach-Volland S., et al. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope 114 (2004) 1856-1860
11. Marchese-Ragona R., Galzignato P.F., Marioni G., et al. Endoscopic diagnosis of rhino-parotid fistula and successful treatment with botulinum toxin. Laryngoscope 115 (2005) 2062-2064
12. Marchese-Ragona R., Marioni G., Restivo A.D., et al. The role of botulinum toxin in postparotidectomy fistula treatment. A technical note. Am J Otolaryngol 27 (2006) 221-224
13. Capaccio P., Paglia M., Minorati D., et al. Diagnosis and therapeutic management of iatrogenic parotid sialocele. Ann Otol Rhinol Laryngol 113 (2004) 562-564
14. Capaccio P., Cuccarini V., Benicchio V., et al. Treatment of iatrogenic submandibular sialocele with botulinum toxin. Case report. Br J Oral Maxillofac Surg 45 (2007) 415-417
15. Arnaud S., Batifor D., Goudot P., et al. Nonsurgical management of traumatic injuries of the parotid gland and duct using type A botulinum toxin. Plast Reconstr Surg 117 (2006) 2426-2430
16. Porta M., Gamba M., Bertacchi G., et al. Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry 70 (2001) 538-540
17. Dogu O., Apaydin D., Sevim S., et al. Ultrasound-guided versus "blind" intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 106 (2004) 93-96
18. Drobik C., and Laskawi R. Frey's syndrome: treatment with botulinum toxin. Acta Otolaryngol Stockh 115 (1995) 459-461
19. Laccourreye O., Muscatelo L., Naude C., et al. Botulinum toxin type A for Frey's syndrome: a preliminary prospective study. Ann Otol Rhinol Laryngol 107 (1998) 52-55
20. Laskawi R., Drobik C., and Schonebeck C. Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome). Laryngoscope 108 (1998) 381-384
21. Restivo D.A., Lanza S., Patti F., et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 59 (2002) 1971-1973
22. Drummond P. Mechanism of gustatory flushing in Frey's syndrome. Clin Auton Res 12 (2002) 144-146
23. Van Weel C. Functional status in primary care: COOP/WONCA charts. Disabil Rehabil 15 (1993) 96-101
24. Lipp A., Trottenberg T., Schink T., et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 61 (2003) 1279-1281
25. Shaw J.E., Abbott C.A., Tindle K., et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 40 (1997) 299-301
26. Hokfelt T., Johansson O., Ljungdahl A., et al. Peptidergic neurones. Nature 284 (1980) 515-521
27. Song P.C., Schwartz J., and Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis 13 (2007) 253-260
28. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
29. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-42
30. Ellies M., Schutz S., Quondamatteo F., et al. Immunohistochemical investigations of the influence of botulinum toxin A on the immunoreactivity of nNOS in the parotid gland of the rat. J Oral Maxillofac Surg 64 (2006) 397-401